SC
OREX

Sculptor Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sculptor Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,200
Closed -$35K – 293
2017
Q4 		$35K Hold
27,200
– – ﹤0.01% 312
2017
Q3 		$58K Hold
27,200
– – ﹤0.01% 348
2017
Q2 		$79K Sell
27,200
-3,400
-11% -$10.2K ﹤0.01% 312
2017
Q1 		$105K Buy
+30,600
New +$121K ﹤0.01% 300

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Sculptor Capital's OREX Position: Q1 2018 in Review

Sculptor Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 27,200 shares — an estimated $35K sold.

Sculptor Capital first reported a position in OREX in Q1 2017 and held it in 4 quarters. The position peaked at $105K in Q1 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • Sculptor Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Sculptor Capital sold 27,200 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $35K.
  • Sculptor Capital first reported a position in Orexigen Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
  • Sculptor Capital's Orexigen Therapeutics, Inc. position peaked at $105K in Q1 2017.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Sculptor Capital's 13F filing for Q1 2018, filed 14 May 2018.